[{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Diazoxide","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Soleno Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Diazoxide","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Controlled Release Tablet","sponsorNew":"Soleno Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Guggenheim Securities","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Public Offering","leadProduct":"Diazoxide","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.070000000000000007,"dosageForm":"Controlled Release Tablet","sponsorNew":"Soleno Therapeutics \/ Guggenheim Securities","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Guggenheim Securities"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Diazoxide","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Controlled Release Tablet","sponsorNew":"Soleno Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Diazoxide","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Controlled Release Tablet","sponsorNew":"Soleno Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Diazoxide","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Controlled-Release Tablet","sponsorNew":"Soleno Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Diazoxide","moa":"Potassium channel","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Controlled-Release Tablet","sponsorNew":"Soleno Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Diazoxide","moa":"Potassium channel","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Extended-release Tablet","sponsorNew":"Soleno Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Oppenheimer & Co.","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Public Offering","leadProduct":"Diazoxide","moa":"AgRP\/NPY protein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.02,"dosageForm":"","sponsorNew":"Soleno Therapeutics \/ Oppenheimer & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Oppenheimer & Co."},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Oppenheimer & Co.","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Public Offering","leadProduct":"Diazoxide","moa":"AgRP\/NPY protein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.02,"dosageForm":"Controlled-release Tablet","sponsorNew":"Soleno Therapeutics \/ Oppenheimer & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Oppenheimer & Co."},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Diazoxide","moa":"AgRP\/NPY protein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Controlled-release Tablet","sponsorNew":"Soleno Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Diazoxide","moa":"Potassium channel","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Prolonged Release Tablet","sponsorNew":"Soleno Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Diazoxide","moa":"Potassium channel","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Prolonged Release Tablet","sponsorNew":"Soleno Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Diazoxide","moa":"Potassium channel","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Prolonged Release Tablet","sponsorNew":"Soleno Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Folia Health","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Diazoxide","moa":"Potassium channel","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Folia Health","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Folia Health"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Diazoxide","moa":"Potassium channel","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Nantahala Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Diazoxide","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.059999999999999998,"dosageForm":"Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Nantahala Capital Management","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Nantahala Capital Management"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Diazoxide","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Diazoxide","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Guggenheim Securities","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"Diazoxide","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.070000000000000007,"dosageForm":"Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Guggenheim Securities","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Guggenheim Securities"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Adage Capital Partners LP","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"Diazoxide","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0.12,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.12,"dosageForm":"Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Adage Capital Partners LP","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Adage Capital Partners LP"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Diazoxide","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Guggenheim Securities","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"Diazoxide","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.070000000000000007,"dosageForm":"Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Guggenheim Securities","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Guggenheim Securities"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Diazoxide","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"Diazoxide","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0.14000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.14000000000000001,"dosageForm":"Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Piper Sandler","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Piper Sandler"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Diazoxide","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Soleno Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Diazoxide","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Soleno Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Soleno Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Diazoxide","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Soleno Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Soleno Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Diazoxide","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Soleno Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Soleno Therapeutics \/ Not Applicable"}]
Find Clinical Drug Pipeline Developments & Deals for Diazoxide
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
